The cluster is small in absolute dollar terms but gains credibility from insider buying. Monitor upcoming Q4 13F filings to see if the buying trend accelerates or if these positions were reversed.
XENE drugs
XENE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 3 $38.23entry
- T+1 · 13d ago +2.51%α +0.86% · $39.19
- T+5 · 7d ago +8.27%α +8.85% · $41.39
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
How similar events traded
Executive Summary
Four asset managers added to their XENE positions in Q3 2026, while one trimmed a tiny stake. The cluster is small in dollar terms ($6.1M aggregate current holdings) but is corroborated by open-market insider buying of $1.7M, including C-suite purchases, suggesting conviction behind the thesis.
Key Financial Metrics
Institutional Positions
Net institutional flow: -$1.2M
▲ Buyers (4)
| Institution | Action | Change | Position Value | Value Δ |
|---|---|---|---|---|
| Strs Ohio | ADD | +42% | $729.0K | -$104.0K |
| Principal Financial Group | ADD | +80.8% | $505.0K | $52.0K |
| Alps Advisors | ADD | +31.4% | $4.8M | -$1.1M |
| Nisa Investment Advisors | ADD | +25.5% | $85.0K | -$25.0K |
▼ Sellers (1)
| Institution | Action | Change | Prev Value | Value Δ |
|---|---|---|---|---|
| Farther Finance Advisors | TRIM | -55.6% | $13.0K | -$9.0K |
Key Facts
- 4 institutional buyers added shares in Q3 2026 (Strs Ohio, Principal Financial Group, Alps Advisors, Nisa Investment Advisors)
- 1 seller (Farther Finance Advisors) trimmed a negligible 96-share position
- Aggregate current holdings of buyers: $6.1M; net change across all buyers: -$1.2M (driven by share price decline, not selling)
- Insider buying of $1.7M (2 open-market buyers including C-suite) corroborates the cluster with a 76/100 confluence score
- Top 13F holders as of Q2 2026: Fidelity ($582M), BlackRock ($454M), Avoro Capital Advisors ($349M)
Financial Impact
4 institutions added shares worth $6.1M in aggregate current value; net dollar change across all buyers was -$1.2M (due to share price decline, not net selling). One seller trimmed $9K.
Risk Factors
- 13F data is 45+ days stale; positions may have been unwound since quarter-end
- Aggregate dollar amounts are small relative to $3.6B market cap and top holders' positions
- All buyers are asset managers (not activist or event-driven funds), limiting signal intensity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 institutional 13F filing from SEC EDGAR.
| Document | Accession Number |
|---|---|
| INST-CLUSTER Data (Synthetic) | inst-cluster-XENE-2026-Q3 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $37.68 to $39.17 ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Viewing Entry $38.23 to $39.19 ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers